Mindmed completes enrollment of phase 2b trial of mm-120 in generalized anxiety disorder (gad)

New york--(business wire)---- $mnmd--mindmed has completed enrollment and dosing in study mmed008, the phase 2b study evaluating mm-120 (lysergide d-tartrate) for the treatment of gad.
MNMD Ratings Summary
MNMD Quant Ranking